Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Chikungunya

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44363   clinical trials with a EudraCT protocol, of which   7387   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    7 result(s) found for: Chikungunya. Displaying page 1 of 1.
    EudraCT Number: 2015-004037-26 Sponsor Protocol Number: MV-CHIK-202 Start Date*: 2017-04-11
    Sponsor Name:Themis Bioscience GmbH
    Full Title: Double blinded, randomized, Priorix®- and placebo-controlled, trial to evaluate the optimal dose of MV-CHIK vaccine (against Chikungunya virus) in regard to immunogenicity, safety and tolerability ...
    Medical condition: The MV-CHIK vaccine candidate is developed to prevent infection with the mosquito borne Chikungunya Virus. This Phase 2 trial is designed to investigate the immunogenicity, safety and tolerability ...
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10067256 Chikungunya virus infection PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2023-001124-42 Sponsor Protocol Number: EBSICV317004 Start Date*: 2024-02-13
    Sponsor Name:Bavarian Nordic A/S
    Full Title: A Phase 3 Safety, Immunogenicity, and Lot-Consistency Trial of the VLP-Based Chikungunya Vaccine PXVX0317 in Healthy Adults and Adolescents
    Medical condition: Healthy Volunteers (Chikungunya disease. Prevention of Chikungunya disease by use of a vaccine)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10067256 Chikungunya virus infection PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2025-000141-10 Sponsor Protocol Number: EBSI-CV-317-006 Start Date*: 2025-06-02
    Sponsor Name:Bavarian Nordic A/S
    Full Title: EBSI-CV-317-006: A Phase 3 Global, Randomized, Double-blind, Placebo-controlled, Safety and Immunogenicity Study of CHIKV VLP Vaccine in Children 2 to <12 Years of Age
    Medical condition: Healthy Volunteers (Chikungunya disease. Prevention of Chikungunya disease by use of a vaccine.)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10067256 Chikungunya virus infection PT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2006-006165-17 Sponsor Protocol Number: L00013 CP 301 Start Date*: 2006-12-27
    Sponsor Name:PIERRE FABRE MEDICAMENT
    Full Title: EFFICACY OF AN EARLY ADMINISTRATION OF L0013CP 10 MG/DAY VERSUS PLACEBO DURING 4 WEEKS IN THE TREATMENT OF INFECTIOUS DISEASES INDUCED ARTHRITIS PAINFUL SYMPTOMS. A MULTICENTER, RANDOMISED, DOUBLE ...
    Medical condition: CHIKUNGUNYA FEVER.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-000211-25 Sponsor Protocol Number: MV-CHIK-205 Start Date*: 2018-07-27
    Sponsor Name:Themis Bioscience GmbH
    Full Title: Observer blinded, randomised study to investigate safety, tolerability and long-term immunogenicity of different dose regimens and formulations of MV-CHIK in healthy volunteers
    Medical condition: The study is being conducted in healthy volunteers for the prophylaxis of chikungunya virus (CHIKV) infection.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2024-000481-17 Sponsor Protocol Number: EBSI-CV-317-008 Start Date*: 2025-08-28
    Sponsor Name:Bavarian Nordic A/S
    Full Title: A Long-term Follow-up Study to Evaluate Safety and Immunogenicity of a Chikungunya Virus Virus-like Particle Vaccine (PXVX0317) in Healthy Adults and Adolescents After Either a Single or a Booster ...
    Medical condition: Healthy Volunteers (Chikungunya disease. The study evaluates safety and immunogenicity)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10067256 Chikungunya virus infection PT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2015-003556-44 Sponsor Protocol Number: IMEA048 Start Date*: 2016-05-17
    Sponsor Name:IMEA Fondation Leon Mba
    Full Title: Phase 2 Randomized, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of a Chikungunya Virus-Like Particle Vaccine,VRC-CHKVLP059-00-VP, in Healthy Adults
    Medical condition: To evaluate the safety and tolerability of VRC-CHKVLP059-00-VP vaccin in healthy adults that reside in CHIKV endemic .
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon Nov 03 17:51:04 CET 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA